
|Videos|January 26, 2018
FDA Approval of Second Dosing Schedule of Nivolumab
Advertisement
Episodes in this series

Hello and welcome to OncLive News Network, Breaking News. I'm Gina Columbus.
The FDA has approved a second dosing schedule for the PD-1 inhibitor nivolumab across all of the PD-1 inhibitor's monotherapy indications. This now allows physicians to prescribe the new dosing schedule of 480 mg of nivolumab every 4 weeks.
Nivolumab is currently approved as a single agent for advanced melanoma, advanced non-small cell lung cancer, advanced renal cell carcinoma, metastatic urothelial carcinoma, Hodgkin lymphoma, and advanced head and neck squamous cell carcinoma.
For more breaking news, subscribe to email alerts from OncLive.com. Thank you for watching! I'm Gina Columbus.
Advertisement
Related to this article

The FDA granted fast track designation to elticertinib for pretreated EGFR exon 20 insertion–mutated NSCLC.

Phase 2 NB2012 data showed a 3-year event-free survival rate of 73.7% with daretabart plus induction chemotherapy.

Deepa Rangachari, MD, discusses community oncology training, goal-concordant mentorship, genomic fluency, and multidisciplinary care.

Mayo Clinic researchers identified BRCA2 variants linked to moderate breast cancer risk, potentially informing personalized screening and prevention.

Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.

Maintenance galinpepimut-S extended overall survival in transplant-ineligible AML in second or later remission.

Longer follow-up of KANDLELIT-001 supports frontline calderasib plus pembrolizumab in KRAS G12C–mutated metastatic non–small cell lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma
2
Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLC
3
Galinpepimut-S Improves OS in AML in Second or Later Remission
4
ESMO 2026 Data Highlight ADC Activity in Brain Metastases and TNBC
5







